No benefit from adjuvant sunitinib or sorafenib for clear cell renal cancerMarch 9, 2017Renal Cell CarcinomaGenitourinary Cancer
Chemo gives no boost to ADT for patients with localized prostate cancerMarch 1, 2017Genitourinary Cancer
Genomic differences seen in mRCC during first- and second-line therapyFebruary 28, 2017Genitourinary CancerRenal Cell CarcinomaImmuno-oncology
Single BEP adjuvant chemotherapy cycle ‘sufficient’ in testicular cancerFebruary 23, 2017Genitourinary Cancer
Chemoradiation standard of care in muscle-invasive bladder cancerFebruary 23, 2017Genitourinary Cancer
No AR in CTCs linked with better survival in advanced prostate cancerFebruary 17, 2017Genitourinary Cancer
RNA-based biopsy test bests NCCN risk stratification for PC prognosisFebruary 17, 2017Genitourinary Cancer
Clinical benefit persists for some with mRCC after stopping immune checkpoint blockadeFebruary 15, 2017Genitourinary CancerRenal Cell Carcinoma
Circulating tumor DNA could guide therapy for advanced prostate cancerFebruary 14, 2017Genitourinary Cancer
